Limited Competition: Clinical Centers for the Halt-Polycystic Kidney Disease Trials (U01)

The summary for the Limited Competition: Clinical Centers for the Halt-Polycystic Kidney Disease Trials (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition: Clinical Centers for the Halt-Polycystic Kidney Disease Trials (U01): -Purpose: The purpose of this limited competition is to continue patient follow-up and complete the two ongoing HALT-Polycystic Kidney Disease (PKD) clinical trials. The HALT-PKD Trials are comprised of two studies (A and B) and are both currently in the patient enrollment phase. HALT-PKD Study A is evaluating the impact of renin-angiotensin-aldosterone system (RAAS) blockade on progression of disease in 548 hypertensive PKD patients with estimated glomerular filtration rate (GFR) > 60ml/min/1.73 m2. The primary endpoint of the study is the percent change in total kidney volume, as measured by magnetic resonance imaging (MRI) over time. HALT-PKD Study B is evaluating the impact of RAAS blockade on progression of disease in 472 hypertensive PKD patients with estimated GFR 30-60 ml/min/1.73 m2. The primary endpoint of Study B is a composite endpoint of time to the 50% reduction of baseline estimated GFR, ESRD (initiation of dialysis or preemptive transplant), or death. -Funds Available and Anticipated Number of Awards. The NIDDK intends to commit approximately $3.25 million in FY 2009 to make 4 awards. -Budget and Project Period: The total project period for an application submitted in response to this funding opportunity may not exceed five years.

Federal Grant Title:	Limited Competition: Clinical Centers for the Halt-Polycystic Kidney Disease Trials (U01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-07-504
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.849
CFDA Descriptions:	Kidney Diseases, Urology and Hematology Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	Mar 18, 2008
Posted Date:	Nov 26, 2007
Creation Date:	Nov 26, 2007
Archive Date:	Apr 18, 2008
Total Program Funding:	$4,250,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:	4
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: For profit organizations other than small businesses Small businesses Independent school districts City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments State governments Native American tribal organizations (other than Federally recognized tribal governments) County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Private institutions of higher education
Additional Information on Eligibility: Foreign institutions are eligible to apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Investigations on Primary Immunodeficiency Diseases (R01); • Grants for Basic Research in Glomerular Diseases (R01); • Advances in Polycystic Kidney Disease (R01); • Ancillary Studies of Kidney Disease Accessing Information from Clinical Trials, Epidemiolo...; • Calcium Oxalate Stone Diseases (R01); • Research Grants for Clinical Studies of Kidney Diseases; • Chronic Prostatitis Collaborative Research Network (Cpcrn); • Frequent Hemodialysis Clinical Trials
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...